Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rubin

Showing results (1101-1110 of 1,202) with videos related to

Pageof 121
Sort By:
Circulation|May 29, 2008
Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2Nazzareno Galiè, Horst Olschewski, Ronald J Oudiz, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|October 26, 2019
Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trialVallerie V McLaughlin, Jean-Luc Vachiery, Ronald J Oudiz, et al.
Annals of the Rheumatic Diseases|May 18, 2010
Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT groupJérôme Avouac, Otylia Kowal-Bielecka, David Pittrow, et al.
Plos One|March 29, 2018
Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trialRogério Souza, Richard N Channick, Marion Delcroix, et al.
JACC. Heart Failure|December 3, 2014
Effect of macitentan on hospitalizations: results from the SERAPHIN trialRichard N Channick, Marion Delcroix, Hossein-Ardeschir Ghofrani, et al.
Mbio|July 10, 2025
Exploring β-lactam interactions with DacB1: unraveling optimal therapies for combating drug-resistant <i>Mycobacterium tuberculosis</i>Mary Nantongo, David C Nguyen, Eunjeong Shin, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 8, 2018
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON StudyJ Gerry Coghlan, Richard Channick, Kelly Chin, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2013
Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD32Sarah A Stanley, Tomohiko Kawate, Noriaki Iwase, et al.
Arthritis Research & Therapy|June 25, 2011
Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are neededChristopher P Denton, Jerome Avouac, Frank Behrens, et al.
Diabetes Care|January 26, 2019
A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 DiabetesMaya Fayfman, Rodolfo J Galindo, Daniel J Rubin, et al.
Pageof 121

Showing results (1101-1110 of 1,202) with videos related to

Sort By:
Pageof 121
Circulation|May 29, 2008
Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2Nazzareno Galiè, Horst Olschewski, Ronald J Oudiz, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|October 26, 2019
Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: Results from the AMBITION trialVallerie V McLaughlin, Jean-Luc Vachiery, Ronald J Oudiz, et al.
Annals of the Rheumatic Diseases|May 18, 2010
Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT groupJérôme Avouac, Otylia Kowal-Bielecka, David Pittrow, et al.
Plos One|March 29, 2018
Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trialRogério Souza, Richard N Channick, Marion Delcroix, et al.
JACC. Heart Failure|December 3, 2014
Effect of macitentan on hospitalizations: results from the SERAPHIN trialRichard N Channick, Marion Delcroix, Hossein-Ardeschir Ghofrani, et al.
Mbio|July 10, 2025
Exploring β-lactam interactions with DacB1: unraveling optimal therapies for combating drug-resistant <i>Mycobacterium tuberculosis</i>Mary Nantongo, David C Nguyen, Eunjeong Shin, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 8, 2018
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON StudyJ Gerry Coghlan, Richard Channick, Kelly Chin, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 27, 2013
Diarylcoumarins inhibit mycolic acid biosynthesis and kill Mycobacterium tuberculosis by targeting FadD32Sarah A Stanley, Tomohiko Kawate, Noriaki Iwase, et al.
Arthritis Research & Therapy|June 25, 2011
Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are neededChristopher P Denton, Jerome Avouac, Frank Behrens, et al.
Diabetes Care|January 26, 2019
A Randomized Controlled Trial on the Safety and Efficacy of Exenatide Therapy for the Inpatient Management of General Medicine and Surgery Patients With Type 2 DiabetesMaya Fayfman, Rodolfo J Galindo, Daniel J Rubin, et al.
Pageof 121